MAP2K7 and gastric cancer: Xie et al. (28) showed that ERK pathway activation inhibits the expression of FOXO1; however, we found a significant decrease of ET-1 and FOXO1 expression after inhibiting ERK phosphorylation by the MEK inhibitor PD0325901 in gastric cancer.